
Psychedelic drugs: Follow the money as investors seek to replace Prozac, Zoloft and other drugs
Biotech startups and venture capital funds are investing in once-controversial treatments.
Top Picks:
Lisa M. Krieger is a science writer at The Mercury News, covering research, scientific policy and environmental news from Stanford University, the University of California, NASA-Ames, U.S. Geological Survey and other Bay Area-based research facilities. Lisa also contributes to the Videography team. She graduated from Duke University with a degree in biology. Outside of work, she enjoys photography, backpacking, swimming and bird-watching. Follow her on Facebook.